Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
European Journal of Pharmacology
|
October 24, 1989
The alpha 2-adrenoceptor antagonists idazoxan and yohimbine can unmask the postsynaptic dopamine agonist effects of B-HT 920
L T Meltzer, J N Wiley, T G Heffner
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 1, 1989
Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys
R H Reuning, S B Ashcraft, J N Wiley, et al.
Psychopharmacology
|
January 1, 1988
Evidence for postsynaptic dopamine agonist effects of B-HT 920 in the presence of the dopamine D-1 agonist SKF 38393
L T Meltzer, J N Wiley, A E Williams, et al.
The Journal of Pharmacy and Pharmacology
|
January 1, 1983
Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea-pigs
T R Macgregor, M A Drum, S E Harrigan, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 1, 1989
CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects
T G Heffner, D A Downs, L T Meltzer, et al.
International Journal of Peptide and Protein Research
|
April 1, 1985
Anti-writhing activity of some peptides related to neurotensin and tuftsin
E D Nicolaides, E A Lunney, J S Kaltenbronn, et al.
Psychopharmacology
|
January 1, 1989
Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice
T G Heffner, J N Wiley, A E Williams, et al.
Journal of Pharmacokinetics and Biopharmaceutics
|
August 1, 1983
Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery system
R H Reuning, S H Liao, A E Staubus, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 1, 1995
CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects
L T Meltzer, C L Christoffersen, A E Corbin, et al.
Neuropharmacology
|
January 1, 1997
The pharmacology of the novel and selective sigma ligand, PD 144418
H C Akunne, S Z Whetzel, J N Wiley, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
European Journal of Pharmacology
|
October 24, 1989
The alpha 2-adrenoceptor antagonists idazoxan and yohimbine can unmask the postsynaptic dopamine agonist effects of B-HT 920
L T Meltzer, J N Wiley, T G Heffner
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 1, 1989
Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys
R H Reuning, S B Ashcraft, J N Wiley, et al.
Psychopharmacology
|
January 1, 1988
Evidence for postsynaptic dopamine agonist effects of B-HT 920 in the presence of the dopamine D-1 agonist SKF 38393
L T Meltzer, J N Wiley, A E Williams, et al.
The Journal of Pharmacy and Pharmacology
|
January 1, 1983
Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea-pigs
T R Macgregor, M A Drum, S E Harrigan, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 1, 1989
CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects
T G Heffner, D A Downs, L T Meltzer, et al.
International Journal of Peptide and Protein Research
|
April 1, 1985
Anti-writhing activity of some peptides related to neurotensin and tuftsin
E D Nicolaides, E A Lunney, J S Kaltenbronn, et al.
Psychopharmacology
|
January 1, 1989
Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice
T G Heffner, J N Wiley, A E Williams, et al.
Journal of Pharmacokinetics and Biopharmaceutics
|
August 1, 1983
Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery system
R H Reuning, S H Liao, A E Staubus, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 1, 1995
CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects
L T Meltzer, C L Christoffersen, A E Corbin, et al.
Neuropharmacology
|
January 1, 1997
The pharmacology of the novel and selective sigma ligand, PD 144418
H C Akunne, S Z Whetzel, J N Wiley, et al.
Page
of 2